NCT05272241 Registry of Asthma Characterization and Recruitment 3 (RACR3)
| NCT ID | NCT05272241 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Condition | Asthma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2022-05-06 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2022-05-06 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Childhood Asthma in Urban Settings (CAUSE) studies.
Eligibility Criteria
Inclusion Criteria: 1. Participant is either: 1. At least 18 years old, willing and able to provide informed consent at the time of enrollment 2. Under the age of 18, accompanied by a legal guardian who is willing and able to provide informed consent at the time of enrollment 2. Participant has a primary place of residence within the Office of Management and Budget (OMB)-defined Metropolitan Statistical Area (MSA) Exclusion Criteria: 1. Participant does not speak English or Spanish and/or guardian does not speak English or Spanish 2. Participant does not have access to a phone, either personal or public, with regularity that could be used for scheduling and safety follow-up 3. Past or current medical problems or findings from physical examination or laboratory testing, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may affect the quality or interpretation of the data obtained from the study Participants who are pregnant or lactating will not be excluded or discontinued from the study, but will not undergo any procedures that are prohibited during pregnancy per the Childhood Asthma in Urban Settings 02 (CAUSE-02) Registry for Asthma Characterization and Recruitment 3 (RACR3) Manual of Procedures (MOP)(e.g., allergen skin testing, spirometry) during the pregnancy. Potential participants may be reassessed as outlined in the Protocol CAUSE-02 MOP.
Contact & Investigator
Christine A. Sorkness, RPh, PharmD
STUDY CHAIR
University of Wisconsin School of Medicine and Public Health; Division of Allergy & Immunology
Frequently Asked Questions
Who can join the NCT05272241 clinical trial?
This trial is open to participants of all sexes, studying Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05272241 currently recruiting?
Yes, NCT05272241 is actively recruiting participants. Visit ClinicalTrials.gov or contact National Institute of Allergy and Infectious Diseases (NIAID) to inquire about joining.
Where is the NCT05272241 trial being conducted?
This trial is being conducted at Aurora, United States, Washington D.C., United States, Chicago, United States, Boston, United States and 3 additional locations.
Who is sponsoring the NCT05272241 clinical trial?
NCT05272241 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). The principal investigator is Christine A. Sorkness, RPh, PharmD at University of Wisconsin School of Medicine and Public Health; Division of Allergy & Immunology. The trial plans to enroll 1,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.